Shen et al. (2023) elucidated that Erianin downregulates METTL3 while concomitantly upregulating FTO, thereby enhancing the stability and translation of ALOX12 and P53 mRNAs. This modulation reduces oxidative stress damage and ferroptosis within ccRCC cells, offering a novel mechanism to overcome therapeutic resistance. Notably, Erianin’s ability to target both METTL3 and FTO highlights its potential as a multifaceted agent for ccRCC management (Table 2). This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.